Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2012

View Archived Issues

Targacept presents results for its nicotinic acetylcholine receptor agonists

Sunovion completes acquisition of Elevation Pharmaceuticals

Health Canada approves Dermagraft for diabetic foot ulcers

Epizyme begins phase I trial of EPZ-5676

Thirty-month safety update for Xiaflex

Results from three clinical studies reported for AZD-5069

Indian researchers disclose novel DNA alkylating agents

Roche synthesizes new dual D3/5-HT2A receptor ligands

Canadian group patents novel antimicrobial steroid alkaloids

Roche and Siena Biotech disclose novel BACE inhibitors

UPenn patents new vaccines for HBV

Almirall presents phase III study results for aclidinium bromide in patients with COPD

Spectrum completes acquisition of Allos Therapeutics

FDA clears Soligenix's IND for SGX-203 for pediatric Crohn's disease

Omeros files IND with FDA for OMS-824 in cognitive disorders

Apremilast demonstrates significant clinical benefit in phase III studies

Sunovion Pharmaceuticals submits supplemental NDAs to the FDA for Latuda

Durata Therapeutics completes target enrollment in DISCOVER 1 trial

ILLUMINATE, SHINE and ENLIGHTEN study results presented

Orexo submits NDA for sublingual buprenorphine/naloxone product

Astex Pharmaceuticals enters epigenetic drug discovery collaboration

New award supports StemCells' development of HuCNS-SC for Alzheimer's disease

FDA grants priority review to Janssen's bedaquiline

FDA advisory committee recommends approval of tobramycin inhalation powder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...